Cancer research has always been important to the Washington based company, Seattle Genetics. President and Co-founder Clay Siegall explained in a recent article with Seattlebusinessmag.com, that while the company is interested in growth they also want to make a sizable impact in the oncological field. One drug that has shown promise for Seattle Genetics is Adcetris. While this drug is still in testing, it has shown substantial promise and already been fast-track approved by the Food and Drug Administration as an alternative line of treatment for Hodgkin’s Lymphoma. Pending its final results, Siegall is confident that Adcetris will become a stable in oncological medicine. In addition to this drug, Siegall is excited for the introduction of three other drugs dedicated to the treatment of cancer. While these drugs are still unnamed they are already working through the rigorous testing required of oncology drugs and will hopefully be available to the public, pending substantial results. Siegall makes is clear that while Seattle Genetics is a company that is at the forefront of pharmaceutical technology, they are also interested in helping the people that depend on their life-saving medicine. He explains that Seattle Genetics is not only interested in introducing new drugs, but quality products with promising futures in medical treatment.
To understand Siegall’s motivation, it is important to understand his background. Before his career in pharmaceuticals, Siegall obtained his B.S. in Zoology from the University of Maryland and a Ph.D. in Genetics from George Washington University. His study in genetics served him well as he worked a variety of jobs in the pharmaceutical industry. One major job for Siegall was his time with the National Cancer Institute. This is where he developed his love of cancer research and it would eventually set the trajectory of his future company, Seattle Genetics.
While Siegall has poured an enormous amount of love and dedication into his work with Seattle Genetics, he has also shared his wealth of knowledge with other biotech companies. Currently, Siegall sits on the board of directors for Ultragenyx and Alder BioPharmaceuticals. While these companies each have different focuses, his positions within them have given him invaluable experience that he can translate into his everyday work. Since the founding of Seattle Genetics, Clay Siegall has proved that he is a formidable man in the world of biotechnology and for now, it seems there is nothing stopping Seattle Genetics as it moves confidently towards the future.